These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 24371012)

  • 21. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
    Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
    Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
    Danchin N; Aïssaoui N
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):325-30. PubMed ID: 20714797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
    Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
    Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ticagrelor vs prasugrel one-month maintenance therapy: impact on platelet reactivity and bleeding events.
    Alexopoulos D; Stavrou K; Koniari I; Gkizas V; Perperis A; Kontoprias K; Vogiatzi C; Bampouri T; Xanthopoulou I
    Thromb Haemost; 2014 Sep; 112(3):551-7. PubMed ID: 24990396
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
    Joshi RR; Hossain R; Morton AC; Ecob R; Judge HM; Wales C; Walker JV; Karunakaran A; Storey RF
    Platelets; 2014; 25(6):416-22. PubMed ID: 24111601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
    Steiner S; Moertl D; Chen L; Coyle D; Wells GA
    Thromb Haemost; 2012 Aug; 108(2):318-27. PubMed ID: 22627948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Myocardial infarction: Role of new antiplatelet agents].
    Silvain J; Bellemain A; Ecollan P; Montalescot G; Collet JP
    Presse Med; 2011 Jun; 40(6):615-24. PubMed ID: 21511430
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, controlled study.
    Schnorbus B; Daiber A; Jurk K; Warnke S; König J; Krahn U; Lackner K; Munzel T; Gori T
    BMJ Open; 2014 May; 4(5):e005268. PubMed ID: 24801283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
    Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
    JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
    Enar R
    Turk Kardiyol Dern Ars; 2013 Mar; 41(2):166-71. PubMed ID: 23666308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
    Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus.
    Ndrepepa G; Kastrati A; Menichelli M; Neumann FJ; Wöhrle J; Bernlochner I; Richardt G; Witzenbichler B; Sibbing D; Gewalt S; Angiolillo DJ; Hamm CW; Hapfelmeier A; Trenk D; Laugwitz KL; Schunkert H; Schüpke S; Mayer K
    JACC Cardiovasc Interv; 2020 Oct; 13(19):2238-2247. PubMed ID: 33032712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
    Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
    Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effect of ticagrelor versus prasugrel on coronary blood flow velocity in patients with non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: an exploratory study.
    Alexopoulos D; Moulias A; Koutsogiannis N; Xanthopoulou I; Kakkavas A; Mavronasiou E; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2013 Jun; 6(3):277-83. PubMed ID: 23735473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
    Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiplatelet therapy in patients with ST-elevation myocardial infarction undergoing myocardial revascularisation: beyond clopidogrel.
    Wouter Jukema J; Collet JP; De Luca L
    Curr Med Res Opin; 2012 Feb; 28(2):203-11. PubMed ID: 22181345
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.